Are steady generic drug price hikes coming to an end?

Or at the very least, a slowdown?

By Nicole Gray • April 23, 2015

Inside Gilead's ambitious new hep C elimination project in Georgia

Gilead will provide free hepatitis C drugs to infected residents of the Eurasian nation in an effort to create a hep C-free zone.

By Nicole Gray • April 23, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Benefits manager warns Vertex's cystic fibrosis Kalydeco combo too pricey

Prime Therapeutics has estimated that the new combo treatment would cost the healthcare system $4.5 billion. 

By Nicole Gray • April 17, 2015

Why did Rx drug spending in the US reach an all-time high in 2014?

Prescription drug sales increased 13% year over year, to $374 billion. Many onlookers are asking why.

By Nicole Gray • April 15, 2015

Glaxo to tweak unique US sales rep compensation plan amid complaints

Glaxo launched the Patient First program four years ago in an effort to discourage purely volume-based prescriptions. But it hasn't exactly been smooth sailing for reps.

By Nicole Gray • April 14, 2015

Angelina Jolie-driven surge in pricey genetic test requests has payers on edge

Medical researchers have dubbed the increased demand for genetic testing the "Angelina effect."

By Nicole Gray • April 13, 2015

Sanofi digs in heels, won't discount Lantus insulin successor Toujeo

The decision may make it more difficult for the company to win over skeptics unsure of how much of an improvement the products is over the blockbuster Lantus.  

By Sy Mukherjee • April 13, 2015

Billionaire Fidelity CEO betting big on cancer companies with personal money

Abigail Johnson, a billionaire, has invested personal money in Coherus Biosciences, Adaptimmune Therapeutics, ViewRay, and Blueprint Medicines Corp.

By Nicole Gray • April 10, 2015

3rd largest Medicaid program didn't spend a dime on Sovaldi due to high cost

Public and private payers alike say they've been struggling with the pricey hep C cure, and Texas' Medicaid program is no exception.

By Sy Mukherjee • April 9, 2015

Amgen CEO scores big pay package on record profits

Robert Bradway earned $14 million last year. 

By Nicole Gray • April 7, 2015

Pfizer to immediately cease vaccine sales in China over licensing spat

The Chinese government did not renew an import license for the pneumococcal vaccine Prevenar.

By Sy Mukherjee • April 2, 2015

Amgen loses Neupogen biosimilar battle—again

The request was intended to delay the introduction of biosimilar Neupogen (filgrastim).

By Nicole Gray • April 1, 2015

Provocative: Analyst says hot new PD-1 cancer drugs are massively overrated

Analyst Amit Roy says that drugs' global market will only be about $10 billion annually—a mere fraction of more optimistic estimates.

By Nicole Gray • April 1, 2015

Glaxo settles J&J suit over allergy med advertisement claims

Johnson & Johnson accused GSK of making false claims about its OTC allergy therapy, Flonase, at the expense of J&J's Benadryl and Zyrtec. 

By Nicole Gray • March 31, 2015

Glaxo finally strikes UK deal for Bexsero that eluded Novartis

Until recently, Novartis owned this meningitis B vaccine, and was in a price stand-off with the British government. 

By Nicole Gray • March 30, 2015

Confirmed: Sanofi's Toujeo launches in US Monday, setting up diabetes race

The next-gen basal insulin was approved in the U.S. on February 25.

By Nicole Gray • March 30, 2015

J&J moving forward in China despite regulatory crackdowns

Are the Chinese government's regulatory restrictions against foreign pharma companies intended to give domestic companies an advantage?

By Nicole Gray • March 27, 2015

How PCSK9 cholesterol drugs will shift pharma's pricing trends

As the new ultra-potent treatment option winds its way through the review process, payers are starting to address cost.

By Nicole Gray • March 25, 2015

The Biogen ripple effect: Analyst recommends Genworth as proxy buy

According to a Raymond James analyst, if Biogen's Alzheimer's drug is approved, it could reduce claims at Genworth Financial—and increase profits.

By Nicole Gray • March 24, 2015

ICYMI: Why 2015 is the year of the biopharma blockbuster (with charts)

11 new products could reach blockbuster status by 2019, compared to just three products from 2014.

By Sy Mukherjee • March 24, 2015

Paper: SSRIs impact teens' sexual function, too

Although many teen patients who take SSRIs—and their physicians—are reluctant to talk about drug-related sexual side effects, they do exist.

By Nicole Gray • March 24, 2015

Here comes the blockbuster: Novartis' Cosentyx bests Stelara in psoriasis trials

Since the drug's approval in January, Novartis has been racking up positive clinical trial data for Cosentyx, showing superiority to both Amgen's Enbrel and now J&J's Stelara.

By Nicole Gray • March 23, 2015

Judge refuses to block Novartis biosimilar of Amgen drug

Sandoz made history earlier this month when it became the first company to receive an FDA approval for a biosimilar.

By Nicole Gray • March 20, 2015

MSF: Sovaldi profit protection measures squeeze out patients in poor nations

Medecins Sans Frontieres says the company's efforts to prevent cheaper Sovaldi (sofosbuvir) from going to rich patients has inadvertently hurt hepatitis C-infected people in poor countries. 

By Nicole Gray • March 18, 2015

New obesity drugs jockey for market uptake

The brave new world of weight-loss drugs has grown in the last few years. But clinicians and patients are still wary of cardiovascular risk. 

By Nicole Gray • March 18, 2015